KinDex Therapeutics is focused on the discovery of molecules that modulate key metabolic regulatory networks associated with chronic disease. The principle targets for KinDex Therapeutics are the regulatory nodes embedded in kinase signaling networks that control genetic expression patterns associated with insulin resistance, Type 2 diabetes, cardio metabolic syndrome, and obesity.

KinDex Therapeutics has a portfolio of lead molecules that have demonstrated a novel mechanism of action in their ability to safely regulate the disturbed regulatory networks related to the etiology of Type 2 diabetes and obesity. 

KinDex Therapeutics will be pursuing an FDA Investigation New Drug regulatory process for its discoveries.

Learn more at kindexus.com 

Board of Directors

Tom Curran, M.B.A., L.L.D.
Alticor, Inc.

Jeff Katke
Metagenics, Inc.

Paul Schimmel, Ph.D.
Lead Independent Director – Schimmel-Yang Laboratory, Scripps Institute

Jeffrey Bland, Ph.D.
Chairman